| 1. |
Prior JC, Langsetmo L, Lentle BC, et al. Ten-year incident osteoporosis-related fractures in the population-based Canadian multicentre osteoporosis study-Comparing site and age-specific risks in women and men. Bone 2015; 71:237-43.
|
| 2. |
Berglundh S, Malmgren L, Luthman H, et al. C-reactive protein, bone loss, fracture, and mortality in elderly women: a longitudinal study in the OPRA cohort. Osteoporos Int 2015; 26:727-35.
|
| 3. |
Mitchell BD, Streeten EA. Clinical impact of recent genetic discoveries in osteoporosis. Appl Clin Genet 2013; 6: 75-85.
|
| 4. |
Lee SH, Lee SW, Ahn SH, et al. Multiple gene polymorphisms can improve prediction of nonvertebral fracture in postmenopausal women. J Bone Miner Res 2013; 28: 2156-64.
|
| 5. |
Otrock ZK, Mahfouz RA, Charafeddine KM, et al. Vitamin D receptor genotypes and response to zoledronic acid therapy in thalassemia-induced osteoporosis. Ann Hematol 2008; 87:947-8.
|
| 6. |
Sai AJ, Gallagher JC, Fang X. Effect of hormone therapy and calcitriol on serum lipid profile in postmenopausal older women: association with estrogen receptor-α genotypes. Menopause 2011; 18:1101-12.
|
| 7. |
Kruk M, Ralston SH, Albagha OM. LRP5 polymorphisms and response to risedronate treatment in osteoporotic men. Calcif Tissue Int 2009; 84:171-9.
|
| 8. |
Zhou PR, Liu HJ, Liao EY, et al. LRP5 polymorphisms and response to alendronate treatment in Chinese postmenopausal women with osteoporosis. Pharmacogenomics 2014; 15:821-31.
|
| 9. |
Olmos JM, Zarrabeitia MT, Hernández JL, et al. Common allelic variants of the farnesyl diphosphate synthase gene influence the response of osteoporotic women to bisphos- phonates. Pharmacogenomics J 2012; 12:227-32.
|
| 10 |
Favus MJ. Bisphosphonates for osteoporosis. NEJM 2010; 363:2027-35.
|
| 11 |
Russell RG. Bisphosphonates: the first 40 years. Bone 2011; 49:2-19.
|
| 12 |
Burnett-Bowie SM, Saag K, Sebba A. Prediction of changes in bone mineral density in postmenopausal women treated with once-weekly bisphosphonates. J Clin Endocrinol Metab 2009; 94:1097-103.
|
| 13 |
Emkey R, Delmas PD, Bolognese M, et al. Efficacy and tolerability of once-monthly oral ibandronate (150 mg) and once-weekly oral alendronate (70 mg): additional results from the monthly oral therapy with ibandronate for osteoporosis intervention (MOTION) study. Clin Ther 2009; 31:751-61.
|
| 14 |
Orwoll ES1, Binkley NC, Lewiecki EM. Efficacy and safety of monthly ibandronate in men with low bone density. Bone 2010; 46:970-6.
|
| 15 |
Tsubaki M, Komai M, Itoh T, et al. Nitrogen-containing bisphosphonates inhibit RANKL- and M-CSF-induced osteoclast formation through the inhibition of ERK1/2 and Akt activation. J Biomed Sci 2014; 21:10.
|
| 16 |
Dudakovic A, Wiemer AJ, Lamb KM, et al. Inhibition of geranylgeranyl pyrophosphate synthase induces apoptosis through multiple mechanisms and displays synergy with inhibition of other isoprenoid biosynthetic enzyme. JPET 2008; 324:1028-36.
|
| 17 |
Liu Y, Liu H, Li M, et al. Association of farnesyl diphosphate synthase polymorphisms and response to alendronate treatment in Chinese postmenopausal women with osteoporosis. Chin Med J 2014; 127:662-8.
|
| 18 |
Chen SH, Lin SW, Lin SR, et al. Moiety-linkage map reveals selective nonbisphosphonate inhibitors of human geranylgeranyl diphosphate synthase. J Chem Inf Model 2013; 53:2299-311.
|
| 19 |
Ericsson J, Greene JM, Carter KC, et al. Human geranyl- geranyl diphosphate synthase: isolation of the cDNA, chromosomal mapping and tissue expression. J Lipid Res 1998; 39:1731-9.
|
| 20 |
Cummings SR, Bates D, Black DM. Clinical use of bone densitometry scientific review. JAMA 2002; 288:1889-97.
|
| 21 |
Kanis JA, Melton LJ, Christiansen C, et al. The diagnosis of osteoporosis. J Bone Miner Res 1994; 9:1137-41.
|
| 22 |
Kavanagh KL, Guo K, Dunford JE, et al. The molecular mechanism of nitrogen-containing bisphosphonates as antiosteoporosis drugs. Proc Natl Acad Sci USA 2006; 103:7829-34.
|
| 23 |
Tsubaki M, Kato C, Nishinobo M, et al. Nitrogen-containing bisphosphonate, YM529/ONO-5920, inhibits macrophage inflammatory protein 1 alpha expression and secretion in mouse myeloma cells. Cancer Sci 2008; 99:152-8.
|
| 24 |
Ling Y, Li ZH, Miranda K, et al. The farnesyl-dipho-sphate/ geranylgeranyl-diphosphate synthase of toxoplasma gondii is a bifunctional enzyme and a molecular target of bisphosphonates. J Biol Chem 2007; 282:30804-16.
|
| 25 |
Fisher JE, Rogers MJ, Halasy JM, et al. Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro . Proc Natl Acad Sci USA 1999; 96:133-8.
|
| 26 |
Coxon FP, Helfrich MH, Van’t Hof R, et al. Protein geranylgeranylation is required for osteoclast formation, function, and survival: inhibition by bisphosphonates and GGTI-298. J Bone Miner Res 2000; 15:1467-76.
|
| 27 |
Choi HJ, Choi JY, Cho SW. Genetic polymorphism of geranylgeranyl diphosphate synthase (GGSP1) predicts bone density response to bisphosphonate therapy in Korean women. Yonsei Med J 2010; 51:231-8.
|
| 28 |
Marini F, Brandi ML. Pharmacogenetics of osteoporosis: future perspectives. Calcif Tissue Int 2009; 84:337-47.
|
| 29 |
Benford, HL, McGowan NW, Helfrich MH, et al. Visuali- zation of bisphosphonate-induced caspase-3 activity in apoptotic osteoclasts in vitro . Bone 2001; 28:465-73.
|
| 30 |
Halasy-Nagy JM, Rodan GA, Reszka AA. Inhibition of bone resorption by alendronate and risedronate does not require osteoclast apotosis. Bone 2001; 29:553-9.
|
| 31 |
Ishijima M, Sakamoto Y, Yamanaka M, et al. Minimum required vitamin D level for optimal increase in bone mineral density with alendronate treatment in osteoporotic women. Calcif Tissue Int 2009; 85:398-404.
|
